RHE · Regional Health Properties, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.16M | - | $15.14M | $10.06M | $7.19M | - | $4.22M | $4.33M | $4.13M | - |
| Cost of Revenue | $4.49M | - | $2.47M | - | - | - | - | - | - | - |
| Gross Profit | $16.67M | - | $12.67M | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $6.52M | - | $3.71M | $2.43M | $2.23M | - | $1.22M | $1.23M | $1.63M | - |
| Total Operating Expenses | $21.86M | - | $15.73M | $10.56M | $7.51M | - | $4.53M | $4.11M | $4.42M | - |
| D&A | $722.0K | - | $547.0K | $403.0K | $402.0K | - | $474.0K | $514.0K | $511.0K | - |
| Operating Income | ($702.0K) | - | ($594.0K) | ($508.0K) | ($318.0K) | - | ($300.0K) | $214.0K | ($294.0K) | - |
| Interest Expense | $522.0K | - | $751.0K | $615.0K | $674.0K | - | $677.0K | $669.0K | $674.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.16M) | - | $3.38M | ($1.45M) | ($1.86M) | - | ($982.0K) | ($706.0K) | ($962.0K) | - |
| EPS - Basic | ($0.29) | - | $1.17 | ($0.68) | ($0.94) | - | ($0.52) | ($0.38) | ($0.52) | - |
| EPS - Diluted | ($0.29) | - | $1.17 | ($0.68) | ($0.94) | - | ($0.52) | ($0.38) | ($0.52) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.10M | $3.00M | $1.00M | $400.0K | $500.0K | $582.0K | $500.0K | $700.0K | $800.0K | $1.00M |
| Accounts Receivable | $10.06M | $8.03M | $7.71M | $4.37M | $3.64M | $3.36M | $2.03M | $1.82M | $1.46M | $1.40M |
| Inventory | $1.63M | $1.35M | $1.44M | - | - | - | - | - | - | - |
| Accounts Payable | $7.71M | $6.99M | - | - | - | $3.69M | - | - | - | - |
| Current Assets | $16.23M | $16.29M | - | - | - | $6.82M | - | - | - | - |
| Total Assets | $67.28M | $67.81M | $72.15M | $60.14M | $59.28M | $60.47M | $60.06M | $61.32M | $61.23M | $62.18M |
| Current Liabilities | $25.26M | $24.16M | - | - | - | $20.41M | - | - | - | - |
| Long-term Debt | $34.55M | $34.74M | $48.58M | $48.92M | $49.16M | $49.72M | $49.66M | $50.24M | $50.01M | $50.73M |
| Total Liabilities | $63.55M | $62.77M | $69.00M | $65.59M | $63.44M | $63.38M | $62.44M | $62.74M | $61.96M | $62.00M |
| Stockholders' Equity | ($962.0K) | $349.0K | ($1.54M) | ($5.45M) | ($4.16M) | ($2.92M) | ($2.38M) | ($1.42M) | ($734.0K) | $185.0K |
| Retained Earnings | ($82.93M) | ($81.78M) | ($84.77M) | ($88.43M) | ($86.98M) | ($85.12M) | ($84.55M) | ($83.57M) | ($82.86M) | ($81.90M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($890.0K) | - | - | - | $236.0K | - | - | - | $597.0K | - |
| Investing Cash Flow | ($364.0K) | - | - | - | ($65.0K) | - | - | - | ($55.0K) | - |
| Financing Cash Flow | ($735.0K) | - | - | - | ($587.0K) | - | - | - | ($751.0K) | - |
| CapEx | $364.0K | - | - | - | $65.0K | - | - | - | $55.0K | - |
| Free Cash Flow | ($1.25M) | - | - | - | $171.0K | - | - | - | $542.0K | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 78.8% | - | 83.7% | - | - | - | - | - | - | - |
| Operating margin | -3.3% | - | -3.9% | -5.1% | -4.4% | - | -7.1% | 4.9% | -7.1% | - |
| EBITDA margin | 0.1% | - | -0.3% | -1.0% | 1.2% | - | 4.1% | 16.8% | 5.3% | - |
| Net margin | -5.5% | - | 22.3% | -14.4% | -25.9% | - | -23.2% | -16.3% | -23.3% | - |
| Free cash flow margin | -5.9% | - | - | - | 2.4% | - | - | - | 13.1% | - |
| FCF / Net income | 1.08 | - | - | - | -0.09 | - | - | - | -0.56 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 30.8% | - | 24.5% | 24.2% | 31.0% | - | 29.0% | 28.4% | 39.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -1.7% | - | 4.7% | -2.4% | -3.1% | - | -1.6% | -1.2% | -1.6% | - |
| Return on equity | 120.3% | - | -219.9% | 26.6% | 44.8% | - | 41.3% | 49.8% | 131.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.64 | 0.67 | - | - | - | 0.33 | - | - | - | - |
| Quick ratio | 0.58 | 0.62 | - | - | - | 0.33 | - | - | - | - |
| Cash ratio | 0.04 | 0.12 | - | - | - | 0.03 | - | - | - | - |
| Leverage | ||||||||||
| Debt / Equity | -35.91 | 99.54 | -31.59 | -8.97 | -11.82 | -17.03 | -20.86 | -35.46 | -68.13 | 274.24 |
| Debt / Assets | 0.51 | 0.51 | 0.67 | 0.81 | 0.83 | 0.82 | 0.83 | 0.82 | 0.82 | 0.82 |
| Debt / EBITDA | 1727.30 | - | - | - | 585.23 | - | 285.39 | 69.02 | 230.46 | - |
| Interest coverage | -1.3x | - | -0.8x | -0.8x | -0.5x | - | -0.4x | 0.3x | -0.4x | - |
| Equity multiplier | -69.94 | 194.30 | -46.91 | -11.03 | -14.25 | -20.71 | -25.24 | -43.27 | -83.41 | 336.11 |
| Liabilities / Assets | 0.94 | 0.93 | 0.96 | 1.09 | 1.07 | 1.05 | 1.04 | 1.02 | 1.01 | 1.00 |
| Efficiency | ||||||||||
| Asset turnover | 0.31 | - | 0.21 | 0.17 | 0.12 | - | 0.07 | 0.07 | 0.07 | - |
| Inventory turnover | 2.76 | - | 1.72 | - | - | - | - | - | - | - |
| Days sales outstanding | 173d | - | 186d | 158d | 185d | - | 176d | 153d | 129d | - |
| Days inventory outstanding | 132d | - | 212d | - | - | - | - | - | - | - |
| Days payable outstanding | 627d | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | -321d | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 194.3% | - | 258.3% | 132.5% | 74.2% | - | 2.1% | -46.6% | 5.7% | - |
| Revenue CAGR (3y) | 75.6% | - | 11.1% | 7.5% | 2.6% | - | -14.3% | -12.6% | -16.5% | - |
| Revenue CAGR (5y) | 24.5% | - | 26.0% | 17.2% | 9.6% | - | -2.6% | -4.0% | -5.3% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -120.8% | - | -98.0% | - | -8.2% | - | 25.7% | 15.1% | 60.5% | - |
| Net income growth (YoY) | 38.0% | - | - | -105.2% | -93.9% | - | -0.9% | -3.1% | 51.7% | - |
| EPS growth (YoY) | 69.1% | - | - | -78.9% | -80.8% | - | 0.0% | - | 77.2% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -68.5% | - | - | - | -79.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 76.9% | - | 35.4% | -284.9% | -466.6% | - | - | - | - | -95.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$53.16M totalHealthcare Services Segment$36.05M · 67.8%
Pharmacy Service$11.72M · 22.1%
Real Estate Segment$5.39M · 10.1%
Product / service
$53.16M totalHealth Care Patient Service$36.05M · 67.8%
Pharmacy Revenues$11.71M · 22.0%
Rental Revenue$5.40M · 10.2%
Peer comparison
Same SIC group: Lessors of Real Property, NEC
Comparing REGIONAL HEALTH PROPERTIES against the 5 most active filers in the same SIC group.